Eva Petkova

List of Publications by Year
in descending order

51 papers	**2,064** citations	279798 **23** h-index	254184 **43** g-index
53 all docs	**53** docs citations	**53** times ranked	**3844** citing authors

#	Article	IF	Citations
1	Functional additive models for optimizing individualized treatment rules. Biometrics, 2023, 79, 113-126.	1.4	2
2	Elucidating Age and Sex-Dependent Association Between Frontal EEG Asymmetry and Depression: An Application of Multiple Imputation in Functional Regression. Journal of the American Statistical Association, 2022, 117, 12-26.	3.1	8
3	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. JAMA Network Open, 2022, 5, e2147331.	5.9	38
4	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. JAMA Network Open, 2022, 5, e2147375.	5.9	30
5	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine, 2022, 182, 115.	5.1	63
6	Multiple Domain and Multiple Kernel Outcome-Weighted Learning for Estimating Individualized Treatment Regimes. Journal of Computational and Graphical Statistics, 2022, 31, 1375-1383.	1.7	1
7	A constrained singleâ€index regression for estimating interactions between a treatment and covariates. Biometrics, 2021, 77, 506-518.	1.4	4
8	Robust index of confidence weighted learning for optimal individualized treatment rule estimation. Stat, 2021, 10, e374.	0.4	2
9	Prospective individual patient data metaâ€analysis: Evaluating convalescent plasma for COVIDâ€19. Statistics in Medicine, 2021, 40, 5131-5151.	1.6	14
10	A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. Journal of the Neurological Sciences, 2021, 426, 117486.	0.6	134
11	Predicting multiscan MRI outcomes in children with neurodevelopmental conditions following MRI simulator training. Developmental Cognitive Neuroscience, 2021, 52, 101009.	4.0	10
12	A single-index model with multiple-links. Journal of Statistical Planning and Inference, 2020, 205, 115-128.	0.6	5
13	A Bayesian approach to joint modeling of matrixâ€valued imaging data and treatment outcome with applications to depression studies. Biometrics, 2020, 76, 87-97.	1.4	6
14	Optimising treatment decision rules through generated effect modifiers: a precision medicine tutorial. BJPsych Open, 2020, 6, e2.	0.7	8
15	Pooling Data From Individual Clinical Trials in the COVID-19 Era. JAMA - Journal of the American Medical Association, 2020, 324, 543.	7.4	63
16	A sparse additive model for treatment effect-modifier selection. Biostatistics, 2020, , .	1.5	5
17	A global needs assessment in times of a global crisis: world psychiatry response to the COVID-19 pandemic. BJPsych Open, 2020, 6, e48.	0.7	134
18	Sleep oscillation-specific associations with Alzheimerâ€™s disease CSF biomarkers: novel roles for sleep spindles and tau. Molecular Neurodegeneration, 2019, 14, 10.	10.8	61

#	Article	IF	Citations
19	Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophrenia Research, 2018, 191, 70-79.	2.0	88
20	Constructing Treatment Decision Rules Based on Scalar and Functional Predictors when Moderators of Treatment Effect are Unknown. Journal of the Royal Statistical Society Series C: Applied Statistics, 2018, 67, 1331-1356.	1.0	10
21	Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. Neuropsychopharmacology, 2018, 43, 2221-2230.	5.4	61
22	Development and evaluation of a multimodal marker of major depressive disorder. Human Brain Mapping, 2018, 39, 4420-4439.	3.6	35
23	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 6, 22-30.	1.1	22
24	History of sexual trauma moderates psychotherapy outcome for posttraumatic stress disorder. Depression and Anxiety, 2017, 34, 692-700.	4.1	27
25	Generated effect modifiers (GEM's) in randomized clinical trials. Biostatistics, 2017, 18, 105-118.	1.5	13
26	Flexible functional regression methods for estimating individualized treatment rules. Stat, 2016, 5, 185-199.	0.4	7
27	Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-β Alterations in a Monkey Model of Type 1 Diabetes. Journal of Neuroscience, 2016, 36, 4248-4258.	3.6	66
28	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. Journal of Psychiatric Research, 2016, 78, 11-23.	3.1	216
29	Patient characteristics as a moderator of posttraumatic stress disorder treatment outcome: combining symptom burden and strengths. BJPsych Open, 2016, 2, 101-106.	0.7	42
30	Effects of ParentCorps in Prekindergarten on Child Mental Health and Academic Performance. JAMA Pediatrics, 2016, 170, 1149.	6.2	54
31	Reduced GABA neuron density in auditory cerebral cortex of subjects with major depressive disorder. Journal of Chemical Neuroanatomy, 2016, 76, 108-121.	2.1	28
32	Stratified psychiatry via convexity-based clustering with applications towards moderator analysis. Statistics and Its Interface, 2016, 9, 255-266.	0.3	4
33	Treatment Decisions Based on Scalar and Functional Baseline Covariates. Biometrics, 2015, 71, 884-894.	1.4	17
34	Reduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice. Neurobiology of Aging, 2015, 36, 1293-1302.	3.1	73
35	D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry,the, 2015, 2, 403-412.	7.4	128
36	Family- and Neighborhood-Level Factors as Predictors of Conduct Problems in School among Young, Urban, Minority Children. Behavioral Medicine, 2015, 41, 177-185.	1.9	6

#	Article	IF	Citations
37	Adverse performance effects of acute lorazepam administration in elderly long-term users: Pharmacokinetic and clinical predictors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 129-135.	4.8	22
38	A Paradoxical Result in Estimating Regression Coefficients. American Statistician, 2014, 68, 271-276.	1.6	13
39	Ongoing Discussion About the US Clinical Lyme Trials. American Journal of Medicine, 2014, 127, e7.	1.5	6
40	Correlates of intentions to use cannabis among US high school seniors in the case of cannabis legalization. International Journal of Drug Policy, 2014, 25, 424-435.	3.3	109
41	Auditory tasks for assessment of sensory function and affective prosody in schizophrenia. Comprehensive Psychiatry, 2014, 55, 1862-1874.	3.1	15
42	Response time intra-subject variability: commonalities between children with autism spectrum disorders and children with ADHD. European Child and Adolescent Psychiatry, 2014, 23, 69-79.	4.7	46
43	Interpreting meta€regression: application to recent controversies in antidepressants€™ efficacy. Statistics in Medicine, 2013, 32, 2875-2892.	1.6	24
44	Cluster (School) RCT of ParentCorps: Impact on Kindergarten Academic Achievement. Pediatrics, 2013, 131, e1521-e1529.	2.1	64
45	Order test for high-dimensional two-sample means. Journal of Statistical Planning and Inference, 2012, 142, 2719-2725.	0.6	4
46	Examining Autistic Traits in Children with ADHD: Does the Autism Spectrum Extend to ADHD?. Journal of Autism and Developmental Disorders, 2011, 41, 1178-1191.	2.7	203
47	Principal point classification: Applications to differentiating drug and placebo responses in longitudinal studies. Journal of Statistical Planning and Inference, 2010, 140, 539-550.	0.6	14
48	Optimal Partitioning for Linear Mixed Effects Models: Applications to Identifying Placebo Responders. Journal of the American Statistical Association, 2010, 105, 968-977.	3.1	19
49	Partitioning of functional data for understanding heterogeneity in psychiatric conditions. Statistics and Its Interface, 2009, 2, 413-424.	0.3	3
50	Order€Preserving Dimension Reduction Procedure for the Dominance of Two Mean Curves with Application to Tidal Volume Curves. Biometrics, 2008, 64, 931-939.	1.4	4
51	Profiling Placebo Responders by Self-Consistent Partitioning of Functional Data. Journal of the American Statistical Association, 2003, 98, 850-858.	3.1	33